Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) Price Target at $16.17

Key Points

• Elanco Animal Health has received a consensus rating of "Moderate Buy" from eight brokerages, with an average 1-year price objective of $16.17.
• Shares of Elanco Animal Health are currently trading at $14.59, down 2.2%, with a market capitalization of $7.25 billion.
• The company's recent earnings report showed a 0.37 EPS, exceeding analyst expectations, and a quarterly revenue of $1.19 billion, reflecting a slight decline compared to the previous year.

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $16.17.

ELAN has been the subject of several research reports. Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. UBS Group raised their price target on shares of Elanco Animal Health from $17.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Leerink Partnrs raised shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. Stifel Nicolaus raised their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. Finally, William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th.

Elanco Animal Health Stock Up 0.2%

NYSE ELAN traded up $0.03 during trading hours on Tuesday, reaching $13.71. 1,315,363 shares of the company's stock were exchanged, compared to its average volume of 5,270,796. The company's 50-day moving average is $14.11 and its two-hundred day moving average is $11.96. Elanco Animal Health has a one year low of $8.02 and a one year high of $15.78. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.46 and a current ratio of 2.71. The company has a market capitalization of $6.81 billion, a price-to-earnings ratio of 18.49, a price-to-earnings-growth ratio of 2.75 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The business had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.17 billion. During the same period in the prior year, the business earned $0.34 EPS. Elanco Animal Health's revenue for the quarter was down 1.0% compared to the same quarter last year. On average, analysts forecast that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Several hedge funds have recently added to or reduced their stakes in ELAN. Resonant Capital Advisors LLC increased its holdings in shares of Elanco Animal Health by 7.9% in the second quarter. Resonant Capital Advisors LLC now owns 31,733 shares of the company's stock valued at $453,000 after purchasing an additional 2,319 shares during the last quarter. DDD Partners LLC lifted its stake in shares of Elanco Animal Health by 10.1% during the 2nd quarter. DDD Partners LLC now owns 1,644,428 shares of the company's stock worth $23,482,000 after buying an additional 151,436 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Elanco Animal Health by 261.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company's stock worth $58,000 after buying an additional 2,922 shares during the last quarter. 180 Wealth Advisors LLC lifted its stake in shares of Elanco Animal Health by 14.8% during the 2nd quarter. 180 Wealth Advisors LLC now owns 37,820 shares of the company's stock worth $540,000 after buying an additional 4,878 shares during the last quarter. Finally, Ethic Inc. lifted its stake in shares of Elanco Animal Health by 57.1% during the 2nd quarter. Ethic Inc. now owns 75,713 shares of the company's stock worth $1,082,000 after buying an additional 27,531 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.